ERBB2 and neoplasm: Immunohistochemical phenotyping of tumours has identified the minimum set of biomarkers required to distinguish these groups; in particular, basal-like and triple-negative (ER-, PR- and HER2-negative) tumours (Blows et al., 2010; Cheang et al., 2008; Nielsen et al., 2004).